We have located links that may give you full text access.
[Normal swallowing spectographic profile in adults].
Nutrición Hospitalaria : Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral 2019 April 11
INTRODUCTION: Introduction: the digital cervical auscultation proposes the spectral identification of sound, including the physical-acoustic phenomenon of normal swallowing processes. For this reason, the evaluative aspects of cervical auscultation are based on the structuring of a spectrographic profile by sections, defined according to the physiological achievement in pharyngeal phase. Method: we use the electronic stethoscope, Littman® model 3200, positioned at point 11 of the neck, which will allow us to make way for the spectrographic analysis procedures in conjunction with the StethAssist software. The data were processed in the Statgraphics Centurion software, which provided statistical description by means of independence tests, in addition to a comparative analysis performed through an ANOVA table and box and whisker chart. Results: the F-test is applied in the ANOVA table; the p-value of the F-test is less than 0.05, so there is a statistically significant relationship between the temporal means of the defined sections, with a level of 95.0% confidence. When proposing the correlation between the biomechanical commands of the pharyngeal phase and the sounds generated by the transport of food, the times found in the spectral analysis of the acoustic wave are needed. Conclusions: a spectral profile of the pharyngeal phase in normal subjects provides the professional parameters of functional interpretation of swallowing, a relevant aspect taking into account the contextual conditions defined in the problem. Cervical auscultation is estimated as a therapeutic accompaniment tool, which can define altered pharyngeal commands.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app